They found a lower hazard ratio (0.64; 95% confidence interval, 0.40–1.02) of relapse-free survival in the adjuvant anti-PD-1 inhibitor group than the interferon/observation group, although the difference did not reach statistical significance [ 82 ].
1
—
—